Abstract: The present invention relates to a heterocyclic modified platinum complex containing an ONCN tetradentate ligand, which has a structure as shown in Chemical Formula (I). The complex is used in organic light-emitting diodes, has a relatively low driving voltage and relatively high luminous efficiency, can significantly prolong the service life of a device, and has the potential for application in the field of organic electroluminescent devices. The present invention further provides an organic electroluminescent device including a cathode, an anode and an organic layer, the organic layer includes one or more layers of a hole injection layer, a hole transport layer, a light-emitting layer, a hole blocking layer, an electron transport layer and an electron injection layer, and at least one layer in the organic layer contains the compound as shown in Structural Formula (I).

Abstract: The present invention provides a freeze-dried composition containing anti-HER2 drug conjugate, which comprises ARX788 and one or more of pharmaceutically acceptable lyoprotectant, buffer salts and surfactants, wherein the pH value of the freeze-dried composition is from 5.7 to 6.3. The present invention also provides a freeze-dried preparation containing anti-HER2 drug conjugate and the preparation method thereof. The present invention also provides use of the freeze-dried composition and the freeze-dried preparation. The freeze-dried composition and the freeze-dried preparation provided by the present invention have a very excellent stability, as well as good appearance, short reconstitution time and low moisture content. The product quality is safe and reliable, and the production efficiency is high.

Abstract: Certain aspects of the present disclosure provide techniques for determining an energy per resource element (EPRE) ratio for non-zero power (NZP) channel state information reference signals (CSI-RSs) when a device is measuring a wireless channel. A method that may be performed by a user equipment (UE) includes determining, based on an indication, an energy per resource element (EPRE) ratio for a non-zero power (NZP) channel state information reference signal (CSI-RS) resource; and measuring a channel based on the determined EPRE ratio and CSI-RSs associated with the NZP CSI-RS resource.

Abstract: Methods, systems, and devices for wireless communications are described. A UE may transmit a capability message to a base station. The capability message may indicate a capability of the UE to monitor a defined number of resources across a set of component carriers (CCs) within a time period. The resources may be channel measurement resources (CMRs) or interference measurement resources (IMRs) for signal to interference plus noise measurement, reference signal (RS) resources for channel state information (CSI) measurement, beam failure detection (BFD), reference signal receive power (RSRP) measurement, link quality monitoring, or different active beams. Based on the capability of the UE, the base station may transmit a monitoring configuration to the UE that indicates a set of resources or active beams for the UE to monitor in the set of CCs. The UE may monitor the defined resources or beams received in the monitoring configuration from the base station.

Abstract: The present disclosure relates to compositions and methods of treating a subject having digestive tract cancer, the method comprising: administering an effective amount of a composition to the subject, the composition comprising a first population of cells comprising a first CAR binding a first antigen, and a second population of cells comprising a second CAR binding GCC, wherein the first antigen comprises a cell surface molecule of a white blood cell (WBC).

Abstract: Described herein are 3-fluoro-4-hydroxybenzamide-containing inhibitors and/or degraders, and pharmaceutical compositions containing 3-fluoro-hydroxybenzamide-containing inhibitors and/or degraders. In some embodiments, the 3-fluoro-4-hydroxybenzamide-containing compounds of the disclosure can be used to treat a condition, for example, nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Abstract: The present disclosure relates to compositions and methods for compositions, methods, and kits for treating cancer using chimeric antigen receptor (CAR) modified cells. Some embodiments of the present disclosure relate to an isolated nucleic acid sequence encoding CAR. The CAR may include an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. The antigen binding domain may bind to an antigen of a non-essential organ.

Abstract: The present disclosure describes compositions and methods for treating solid tumors expressing mesothelin (MSLN) using chimeric antigen receptor (CAR) T cell therapy. The compositions comprise CARs with an extracellular domain that specifically binds MSLN. The extracellular domain comprises a single variable domain (VHH) antibody that targets MSLN. Polynucleotides encoding the anti-MSLN CAR constructs are provided. Pharmaceutical compositions comprising CAR T cells expressing the anti-MSLN CARs are also described. The CAR T cells demonstrate cytotoxicity against MSLN-expressing tumor cells in vitro and anti-tumor activity in vivo. Methods are provided for generating the CAR T cells by transfecting T cells with lentiviral or retroviral vectors carrying anti-MSLN CAR encoding sequences. The anti-MSLN CAR T cell therapy described herein provides an effective approach for treating solid tumors expressing MSLN, such as mesothelioma, ovarian cancer, pancreatic cancer, and lung cancer.

Abstract: Various aspects of the present disclosure generally relate to wireless communication. A UE capability for a multiple physical downlink shared channel (PDSCH) scheduling may be signaled from a UE to a network entity. A UE capability signaling may indicate whether the UE supports a multiple PDSCH scheduling being associated with a same time domain resource allocation (TDRA) and/or a same frequency domain resource allocation (FDRA). The network node may schedule the multiple PDSCHs, via a multiple user multiple-input multiple-output (MU-MIMO) PDSCH scheduling or a multiple downlink control information (multi-DCI) multiple transmission reception point (mTRP) PDSCH scheduling, based at least in part on the UE capability signaling. The network entity may guarantee that co-scheduled PDSCHs have the same TDRA and/or the same FDRA, which may be based at least in part on the UE capability signaling.

Abstract: Embodiments relate to a modified T cell comprising an antigen binding molecule, wherein expression and/or function of CDC42 in the modified cell has been enhanced. In embodiments, the modified cell has an increased level of cytokine release in response to an antigen that the antigen binding molecule binds as compared to a corresponding T cell that does not overexpress CDC42. In embodiments, the cytokine release comprises a cytokine release of IFN?. In embodiments, the modified cell has an enhanced migration capability in response to a chemokine as compared to a corresponding T cell that does not overexpress CDC42.

Abstract: A method for detecting failure of passive wavelength division equipment includes: determining whether base station equipment is pre-modeled; when the base station equipment is not pre-modeled, dividing the first side equipment and the second side equipment in the base station equipment into a plurality of equipment groups; obtaining optical port alarm information of the first side equipment in the base station equipment and/or optical port alarm information of the second side equipment in the base station equipment, or obtaining link disconnection alarm information of the second side equipment in the base station equipment; when no link disconnection alarm information of the second side equipment is obtained, and it is determined, according to the optical port alarm information, that there is an equipment group satisfying a first preset condition, determining that the passive wavelength division equipment corresponding to the equipment group satisfying the first preset condition fails.

Abstract: The compositions and methods described herein are directed to treating solid tumors using CAR T therapy and/or antibodies targeting GCC. The compositions include CAR comprising an extracellular domain that binds GCC.

Abstract: A docker image is received. The docker image is for a container. The container contains files that allow for virtualization of applications that run within the container. The docker image is parsed to identify layer files in the docker image. Installed software components (e.g., installed files) and/or hardware components in the layer files are identified. Software application index calls are made to generate information that identifies relationships between the installed software components and/or hardware components. The relationships between the installed software components and/or hardware components are then displayed to a user.

Abstract: A child crib includes a frame body, a corner component, a cloth component and a covering member. The cloth component at least partially covers the frame body. The corner component is connected to a handrail and a post of the frame body and exposed out of the cloth component. A first ring-shaped opening structure and a second ring-shaped opening structure are respectively formed by a first side and a second side of a covering body of the covering member. When the first side of the covering body is connected to a first side of the cloth component, by positioning the second side of the covering body on a second side of the cloth component, the first side and the second side of the cloth component are respectively enclosed by the first ring-shaped opening structure and the second ring-shaped opening structure, and the covering member covers the corner component.

Abstract: The present disclosure describes compositions and methods for treating cancer. Embodiments relate to a cell modified to express one or more molecules at a level that is higher or lower than the level of the one or more molecules expressed by a cell that has not been modified to express the one or more molecules, wherein the one or more molecules comprise Cavin3, ZBED2, and MYC.

Abstract: Methods, systems, and devices for wireless communications are described. A network entity may transmit a set of spatially multiplexed synchronization signals in a same symbol period. The set of spatially multiplexed synchronization signals may indicate a parameter, such as a cell identifier, for the network entity. The network entity may select a sequence for each synchronization signal of the set. A user equipment (UE) may monitor for the set of spatially multiplexed synchronization signals during the same symbol period. The UE may differentiate each synchronization signal based on a respective sequence used to transmit each synchronization signal. The UE may determine that the set of spatially multiplexed synchronization signals were transmitted by the network entity using multiple antenna ports. The UE may determine the parameter for the network entity based on receiving the set of spatially multiplexed synchronization signals.

Abstract: The present disclosure relates to compositions and methods for compositions, methods, and kits for treating cancer using chimeric antigen receptor (CAR) modified cells. Some embodiments of the present disclosure relate to an isolated nucleic acid sequence encoding CAR. The CAR may include an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. The antigen binding domain may bind to an antigen of a non-essential organ.

Abstract: A food processor and an electric motor for a food processor. The electric motor includes: a stator core having a ring-shaped stator yoke and a plurality of stator teeth provided at an inner peripheral face of the stator yoke, two adjacent stator teeth defining a stator slot there between, the plurality of the stator teeth defining a stator hole coaxial with the stator yoke, and an outer contour of a radial section of the stator yoke being substantially circular and having a maximum radial dimension D; and a rotor core rotatably provided in the stator hole and coaxial with the stator hole, the rotor core having a maximum radial dimension d, in which 0.4?d/D?0.55.

Abstract: The present disclosure relates to compositions and methods for enhancing infiltration of lymphocytes into tumor tissue, enhancing anti-tumor lymphocyte activities in tumor microenvionment (TME), inhibiting regulatory lymphocyte (e.g., B and T cells) activities in TME, and/or long term benefit of cell therapies. For example, in a method of in vivo cell expansion, the method comprises administering an effective amount of cells comprising an antigen binding molecule to a subject; and administering an effective amount of presenting cells expressing a solid tumor antigen that the binding molecule binds.

Abstract: Methods, systems, and devices for wireless communications are described. In some wireless communications systems, a user equipment (UE) and a network entity may utilize multi-port mobility reference signals to assist with spatial based mobility procedures. The UE may receive a reference signal that is associated with multiple antenna ports. The UE may measure a multi-dimensional channel response based on the reference signal. The multi-dimensional channel response may be associated with measured channel metrics corresponding to the multiple antenna ports. The UE may transmit a report that includes a channel measurement vector based on the multi-dimensional channel response. The channel measurement vector may indicate multiple measured channel metrics for one or more dimensions of the multi-dimensional channel response. The network entity may transmit a message that indicates one or more metrics associated with mobility management for the UE based on the report that indicates the channel measurement vector.